Skip to main content
TipRanks
Go Ultimate75% OFF

Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis

1 Followers
HK:2179

Jiangsu Recbio Technology Co., Ltd. Class H

(HKEX:2179)

Select Model
Rating:38Underperform
Price Target:HKD 4.00â–²(2.56% Upside)
Action:reiterated
Date:10/17/26

The score is primarily constrained by persistent losses, substantial cash burn, rising leverage, and negative valuation support. Bearish technical positioning further weakens the outlook, while oversold momentum provides only limited offset.

Positive Factors
Improved LeverageThe reduction in debt relative to equity improves financial flexibility and lowers balance-sheet risk compared with the prior year. Although leverage remains meaningful, this direction of change gives the company a stronger foundation to manage development spending and pursue commercialization over the next several quarters.
Negative Factors
Sharp Revenue ContractionA steep year-over-year revenue decline indicates that commercialization has not yet developed into a stable, repeatable growth engine. Continued volatility makes operating planning more difficult, limits internal funding capacity and increases dependence on future product progress or external financing.

Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-40%-30%-20%-10%0%10%20%HK:2179-35.64%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.76B
Dividend Yield
―
Average Volume (3M)
9,166
Price to Earnings (P/E)
-4.3
Beta (1Y)
0.54
Revenue Growth
-82.46%
EPS Growth
41.19%
Country
Hong Kong
Employees
466
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion o...

How the Company Makes Money

The company makes money primarily through (1) commercialization of its vaccine/biologics products (when approved), generating revenue from product sales to customers in the healthcare supply chain; and (2) out-licensing and/or collaboration arrangeme...

Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview

Summary

Very weak performance: persistent and worsening net losses, negative gross profit, heavy operating cash burn, rising leverage, and deeply negative ROE. Positive equity and manageable debt provide limited support.

Income Statement

12Very Negative

Balance Sheet

38Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.29M12.40M27.00M30.38M5.33M6.20M
Gross Profit-47.33M-91.46M15.95M22.34M5.33M6.20M
EBITDA-357.03M-483.72M-491.04M-553.85M-834.14M-590.00M
Net Income-477.06M-594.59M-562.39M-571.96M-719.20M-657.56M
Balance Sheet
Total Assets1.60B1.76B1.94B2.19B2.31B1.92B
Cash, Cash Equivalents and Short-Term Investments187.51M351.99M448.31M837.76M1.33B1.18B
Total Debt672.99M638.75M889.10M650.79M282.63M76.72M
Total Liabilities1.10B1.06B1.41B1.12B656.53M245.92M
Stockholders Equity497.98M706.14M529.32M1.07B1.66B1.67B
Cash Flow
Free Cash Flow-505.26M-601.50M-636.66M-862.18M-888.04M-710.79M
Operating Cash Flow-445.83M-502.64M-464.82M-638.07M-579.54M-472.92M
Investing Cash Flow-78.43M35.43M-279.04M9.42M-378.43M68.70M
Financing Cash Flow596.88M499.77M218.06M275.27M839.44M1.23B

Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative
Last Price3.90

Price Trends

50DMA4.35Negative
100DMA4.66Negative
200DMA4.72Negative

Market Momentum

MACD-0.11Negative
RSI32.92Neutral
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 3.90 is equal to the 20-day moving average (MA) of 3.90, below the 50-day MA of 4.35, and below the 200-day MA of 4.72, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 32.92 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.

Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:2179 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:6998HK:699870OutperformHKD 3.12B4.2910.99%―1417.68%660.14%
HK:2696HK:269665NeutralHKD 26.24B25.7220.41%―32.63%8.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1875HK:187549NeutralHKD 2.62B-13.12-26.14%―-51.10%-2384.76%
HK:2197HK:219745NeutralHKD 2.16B2.14-64.89%―-99.15%―
HK:1877HK:187741NeutralHKD 30.69B-71.16-7.23%―35.82%54.40%
HK:2179HK:217938UnderperformHKD 2.43B-4.30-79.24%―-82.46%41.19%

* Healthcare Sector Average

Performance Comparison

0%100%200%HK:2179HK:6998HK:1875HK:1877HK:2197HK:2696Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2179 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2179Jiangsu Recbio Technology Co., Ltd. Class H3.90-2.16-35.64%
HK:6998Genor Biopharma Holdings Limited1.55-1.57-50.32%
HK:1875TOT BIOPHARM International Co. Ltd.3.391.5079.37%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H14.95-9.79-39.57%
HK:2197Clover Biopharmaceuticals Ltd.1.67-0.94-36.21%
HK:2696Shanghai Henlius Biotech, Inc. Class H48.12-17.13-26.25%

Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events

Recbio Delays REC603 Vaccine Filing Amid Changing HPV Trends

Nov 9, 2026

Jiangsu Recbio Technology develops innovative vaccines and biopharmaceutical products, including REC603, a recombinant nine-valent HPV vaccine candidate aimed at the Chinese market. REC603 is undergoing a pivotal Phase III trial in China, with long-t...

Recbio Completes Phase III Trial of Novel Shingles Vaccine REC610 in China

Oct 29, 2026

Jiangsu Recbio Technology has completed a Phase III clinical trial of its independently developed novel adjuvanted recombinant shingles vaccine REC610 in China and obtained the trial summary report. The study showed that REC610, designed to prevent h...

Jiangsu Recbio Announces Board-Level Resignation and New Authorised Representative

Aug 25, 2026

Jiangsu Recbio Technology Co., Ltd. announced that executive director and board secretary Mr. Wei Qifang has resigned from his roles, including authorised representative and joint company secretary, effective August 25, 2026, citing personal reasons...

Jiangsu Recbio Sets Out Board Composition and Committee Structure

Aug 25, 2026

Jiangsu Recbio Technology Co., Ltd., a Hong Kong-listed joint stock company based in Jiangsu Province, has detailed the composition of its board of directors, which includes a non-executive chairman, two executive directors, several non-executive dir...

Jiangsu Recbio Clarifies Board Composition and Committee Leadership

Aug 19, 2026

Jiangsu Recbio Technology Co., Ltd., a joint stock biopharmaceutical company based in Jiangsu Province and listed in Hong Kong as a Class H issuer, operates with a multi-tier board comprising executive, non-executive and independent non-executive dir...

Recbio Advances Shingles and HPV Vaccines as Interim Loss Narrows

Aug 19, 2026

Jiangsu Recbio Technology Co., Ltd. reported significant R&D progress in the first half of 2026, led by its novel adjuvanted recombinant shingles vaccine REC610, which has completed Phase III enrollment and dosing in China and advanced to the marketi...

Jiangsu Recbio Formalizes H Share Full Circulation with Amended Articles

Aug 17, 2026

Jiangsu Recbio Technology Co., Ltd. has amended its Articles of Association following the completion of its H Share Full Circulation plan, which converted 141,953,489 previously unlisted shares into H shares. As a result, the company now reports a to...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026